Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GRC 54276 |
Synonyms | |
Therapy Description |
GRC 54276 inhibits MAP4K1 (HPK1), potentially resulting in increased antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 463). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GRC 54276 | GRC-54276|GRC54276 | MAP4K1 Inhibitor 7 | GRC 54276 inhibits MAP4K1 (HPK1), potentially resulting in increased antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 463). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05878691 | Phase I | GRC 54276 + Pembrolizumab Atezolizumab + GRC 54276 GRC 54276 | A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | Active, not recruiting | USA | 1 |